| Primary |
| Product Used For Unknown Indication |
32.4% |
| Anaesthesia |
17.6% |
| General Anaesthesia |
14.7% |
| Antibiotic Prophylaxis |
5.9% |
| Bronchospasm |
5.9% |
| Pain |
5.9% |
| Breast Cancer |
2.9% |
| Colectomy Total |
2.9% |
| Infection Prophylaxis |
2.9% |
| Intestinal Anastomosis |
2.9% |
| Premedication |
2.9% |
| Prophylaxis Of Nausea And Vomiting |
2.9% |
|
| Tachycardia |
40.0% |
| Drug Ineffective |
20.0% |
| Rash Erythematous |
20.0% |
| Urticaria |
20.0% |
|
| Secondary |
| Anaesthesia |
22.4% |
| Drug Use For Unknown Indication |
20.6% |
| Induction Of Anaesthesia |
19.6% |
| General Anaesthesia |
10.9% |
| Product Used For Unknown Indication |
7.4% |
| Antibiotic Prophylaxis |
3.4% |
| Pain |
3.0% |
| Prophylaxis |
2.1% |
| Premedication |
1.3% |
| Thrombosis Prophylaxis |
1.2% |
| Abdominal Pain |
1.1% |
| Breast Operation |
1.0% |
| Postoperative Care |
1.0% |
| Therapeutic Procedure |
1.0% |
| Surgery |
0.9% |
| Bacteroides Infection |
0.6% |
| Enterobacter Infection |
0.6% |
| Induction Of Anesthesia |
0.6% |
| Anesthesia |
0.5% |
| Asthma |
0.5% |
|
| Anaphylactic Shock |
22.3% |
| Tachycardia |
10.2% |
| Shock |
8.9% |
| Toxic Skin Eruption |
7.6% |
| Hypotension |
7.0% |
| Stevens-johnson Syndrome |
5.1% |
| Erythema |
4.5% |
| Urticaria |
4.5% |
| Rash Vesicular |
3.8% |
| Bronchospasm |
3.2% |
| Generalised Erythema |
2.5% |
| Hypersensitivity |
2.5% |
| Pancreatitis Acute |
2.5% |
| Rash |
2.5% |
| Rhabdomyolysis |
2.5% |
| Ventricular Arrhythmia |
2.5% |
| Circulatory Collapse |
1.9% |
| Rash Erythematous |
1.9% |
| Respiratory Failure |
1.9% |
| Toxic Epidermal Necrolysis |
1.9% |
|
| Concomitant |
| Anaesthesia |
17.3% |
| Product Used For Unknown Indication |
15.1% |
| Drug Use For Unknown Indication |
10.4% |
| Induction Of Anaesthesia |
10.4% |
| Premedication |
6.1% |
| Spinal Anaesthesia |
4.3% |
| Third Stage Postpartum Haemorrhage |
4.3% |
| Antibiotic Prophylaxis |
4.0% |
| Hypotonia |
3.2% |
| Renal Transplant |
2.9% |
| Sedation |
2.9% |
| Atrial Fibrillation |
2.5% |
| Infection |
2.5% |
| Neoplasm |
2.5% |
| Acute Myeloid Leukaemia |
2.2% |
| Pain |
2.2% |
| Postpartum Haemorrhage |
2.2% |
| Prophylaxis |
2.2% |
| Anaemia |
1.4% |
| Hypertension |
1.4% |
|
| Tachycardia |
15.8% |
| Anaphylactic Shock |
12.3% |
| Circulatory Collapse |
8.8% |
| Hypotension |
5.3% |
| Septic Shock |
5.3% |
| Sinus Tachycardia |
5.3% |
| Thrombophlebitis Superficial |
5.3% |
| Ventricular Fibrillation |
5.3% |
| White Blood Cell Count Increased |
5.3% |
| Anaphylactoid Shock |
3.5% |
| Cholestasis |
3.5% |
| Dialysis |
3.5% |
| Interstitial Lung Disease |
3.5% |
| Oxygen Saturation Decreased |
3.5% |
| Sepsis |
3.5% |
| Ventricular Hypokinesia |
3.5% |
| Agranulocytosis |
1.8% |
| Anaemia |
1.8% |
| Anxiety |
1.8% |
| Cardiac Arrest |
1.8% |
|
| Interacting |
| General Anaesthesia |
33.3% |
| Hypertension |
33.3% |
| Anaesthesia |
16.7% |
| Induction Of Anaesthesia |
16.7% |
|
|
